Evidence map›Paper›PMID 40269149›Full record

ArticleScientific reports2025

The influence of socio-economic status on the fulfilment of Saint-Gallen recommendations for early-stage breast cancer.

Trinidad Dierssen-Sotos, Inés Gómez-Acebo, Jéssica Alonso-Molero, Beatriz Pérez-Gómez, Marcela Guevara, Pilar Amiano, Gemma Castaño-Vinyals, Alba Marcos-Delgado, Mónica Mirones, Mireia Obón-Santacana and 13 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Trinidad Dierssen-Sotos *Universidad de Cantabria, Santander, Spain.
Inés Gómez-Acebo *Universidad de Cantabria, Santander, Spain.
Jéssica Alonso-Molero *Universidad de Cantabria, Santander, Spain. alonsomj@unican.es.
Beatriz Pérez-GómezBoston College, Boston, MA, USA.
Marcela GuevaraCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Pilar AmianoCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Gemma Castaño-VinyalsCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Alba Marcos-DelgadoGrupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), León, Spain.
Mónica MironesUniversidad de Cantabria, Santander, Spain.
Mireia Obón-SantacanaCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Guillermo Fernández-TardónCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ana Molina-BarcelóCancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.
Juan BayoServicio de Oncología del Hospital Universitario Juan Ramón Jiménez, 21005, Huelva, Spain.
Arantza SanvisensUnitat Epidemiologia I Registre de Càncer de Girona, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Pla director d'Oncologia, Girona, Spain.
María Fernández-OrtizIDIVAL, Santander, Spain.
Tania Fernández-VillaGrupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), León, Spain.
Ana EspinosaCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Amaia AizpuruaServicio de Oncología del Hospital Universitario Juan Ramón Jiménez, 21005, Huelva, Spain.
Eva ArdanazCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Nuria AragonésCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Manolis KogevinasCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Marina PollánCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Javier LlorcaUniversidad de Cantabria, Santander, Spain.

Funding

Conselleria de Sanitat of the Generalitat Valenciana AP_061/10Fundación Marqués de Valdecilla API 10/09Instituto de Salud Carlos III-FEDER PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034, PI18/00181ISCIII RD12/0036/0036Junta de Andalucía PI-0571-2009, PI-0306-2011, salud201200057018traJunta de Castilla y León LE22A10-2Recercaixa 2010ACUP 00310
6 · The paper itself

Abstract

Socio-economic status (SES) is related to breast cancer diagnosis and prognosis. We study if SES is related to the adequacy of the treatment according to Saint Gallen consensus in Spanish women with incident breast cancer. Breast cancer cohort was assembled from incident cases from MCC-Spain and prospective followed-up afterwards. Participants were then classified according to the Saint-Gallen consensus in three categories (In Saint-Gallen, who received therapy accorded by Saint Gallen; Over Saint-Gallen, who received some additional therapy; or Under Saint-Gallen, who did not receive the complete therapy). Association between SES and Saint-Gallen fulfilment was analyzed using multinomial logistic regression, adjusting for clinicopathological and patient-related variables. 1115 patients in stages I and II were included. Women with university education were 58% more likely to receive over Saint-Gallen therapies (RRR = 1.68; 95%CI 0.84-3.33). In the simplified SES score, women with higher SES were over Saint-Gallen 52% more than those with lower SES (RRR = 1.52; 95%CI 0.88-2.64). Women with higher SES more often received over Saint-Gallen therapies. Further analyses are needed to understand the influence of these differences on the overall survival as well as its potential unwanted side effects.

Indexed as

Breast NeoplasmsSocial ClassAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPrognosisProspective StudiesSpainBreast cancerMCC-SpainSaint-Gallen consensusSocio-economic status

Identifiers

PMID40269149
PMCPMC12019212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.